多囊卵巢综合征患者血浆血管活性肠肽水平变化及其潜在病理意义  

Plasma Level of Vasoactive Intestinal Peptide in Patients with Polycystic Ovary Syndrome and its Potential Pathological Significance

作　　者：高霞[1,2] 唐奕[1] 蔡素芬[1] 龚斐[1] 

机构地区：[1]中南大学基础医学院生殖与干细胞工程研究所,湖南长沙410078 [2]长治医学院附属和平医院妇产科

出　　处：《中南医学科学杂志》2015年第6期637-641,657,共6页Medical Science Journal of Central South China

摘　　要：目的比较多囊卵巢综合征(PCOS)患者与正常女性对照人群两组之间血浆血管活性肠肽(VIP)水平的差异,初步探讨VIP在PCOS发生、发展中的潜在病理意义。方法检测体重指数、血浆VIP和性激素水平,分析血浆VIP水平与体重指数、性激素水平的相关性。结果 PCOS患者血浆VIP水平显著低于健康对照女性(408.49±25.80 vs 663.85±71.17 ng/L,P<0.05)。所有受试者血浆VIP水平与体重指数、LH/FSH比值、血浆睾酮浓度呈显著负相关(P<0.05)。结论 VIP可能参与PCOS的病理生理过程,能否作为诊断PCOS或判断其预后的一种新的血浆生物标记物,并成为潜在的治疗新靶点,有待进一步研究证实。Objective To evaluate the difference in plasma level of vasoactive intestinal peptide （ VIP） between pa-tients with polycystic ovary syndrome （ PCOS） and healthy control subjects,and to explore its potential pathological signifi-cance in the genesis and development of PCOS. Methods The body mass index and plasma concentrations of VIP and sex hormone were measured. The relationship between plasma level of VIP with hormonal and metabolic parameters was ana-lyzed. Results The plasma levels of VIP in PCOS patients were significantly lower than that of healthy control subjects （408. 49 ± 25. 80 vs 663. 85 ± 71. 17 ng/L,P〈0. 05）. There was a significantly negative correlation between the plasma VIP concentration with body mass index, LH/FSH ratio and the plasma testosterone concentration in two groups together （P〈0. 05）. Conclusion VIP may participate in the pathophysiological process of PCOS. Whether VIP may be used as a novel plasma biomarker or a prognostic factor for PCOS and as a potential therapeutic target in the clinical setting needs to be further investigated.

关 键 词：血管活性肠肽 多囊卵巢综合征 性激素 肥胖 

分 类 号：R711[医药卫生—妇产科学]